beligas pharmaceuticals tirzepatide Tirzepatide Dual Agonist (GLP-1/GIP) Beligas Pharmaceuticals - Beligas Pharmaceuticals

Pentadeca-Arginate (PDA) is a synthetic peptide with the same number of amino acids as BPC-157, but with a critical difference: it includes an arginine modification that makes it far more stable in acidic environments

It is encoded in the mitochondrial genome and affects insulin sensitivity and cellular metabolism

If a patient's weight loss starts affecting cardiovascular markers or blood sugar, their One Medical provider sees that in real time not six months later at an annual checkup

Additionally, glutathione disulfide (GSSG) plays a crucial role in managing oxidative stress in chronic illnesses by maintaining the balance between reduced and oxidized glutathione

The good news: Tweaking your food choices, especially in the first 48 hours after the shot, can help, says Dr

The novel dual GLP-1 and GIP receptor agonist tirzepatide was approved in 2023 by the FDA for the treatment of obesity, as around a 15% weight loss was observed in the tirzepatide treated patients [45]